MorphoSys to Receive Milestone Payment for Guselkumab Program
News Apr 14, 2015
MorphoSys AG has announced that its collaborator Janssen Biotech, Inc. (Janssen) has initiated a phase 2 clinical trial in psoriatic arthritis with the HuCAL antibody guselkumab (CNTO1959). The event triggered a clinical milestone payment to MorphoSys. Further financial details were not disclosed.
"We are delighted to see Janssen moving guselkumab into a new clinical program for psoriatic arthritis," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "Today's news marks the first of up to six clinical milestone events we expect to see with partners this year."
MorphoSys's collaboration with Janssen has resulted in three clinical programs to date, two of which are in phase 2 development and one, guselkumab, in phase 3 in psoriasis (most advanced trial).
In total, MorphoSys's partnered and proprietary clinical pipeline currently comprises 23 unique antibody molecules which are being evaluated in more than 60 clinical trials.
Study Reveals How MRSA Infection Compromises Lymphatic FunctionNews
Infections of the skin or other soft tissues with the hard-to-treat MRSA bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. Investigators describe how MRSA infection impairs the ability of lymphatic vessels to pump lymphatic fluid to lymph nodes in mouse models, which may contribute to the frequent recurrences of MRSA infection experienced by patients.
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE